echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > FDA issues guidelines for non-clinical research on personalized antisense oligonucleotide therapeutics

    FDA issues guidelines for non-clinical research on personalized antisense oligonucleotide therapeutics

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The U.


    FDA Acting Director Janet Woodcock said that the issuance of the guidelines stems from "greater efforts to clarify the development of new drugs in the era of personalized medicine.


    The draft guidance "is expected to help prepare for adequate pre-IND and IND applications for FDA review, so that clinical trials can be initiated quickly.


    Since the use of research antisense oligonucleotides involved in the guidelines will only target a small number of individuals with severe debilitating or life-threatening diseases, the guidelines recommend non-clinical safety data packages to support FIH exposure The range is generally not as broad as is generally recommended for the development of antisense oligonucleotide products for wider use or in less severe clinical situations.


    The FDA stated that “in order to compensate for the greater risks posed by limited data,” sponsors should provide “convincing in vitro and/or in vivo proof-of-concept (POC) data” to support the application.


    The FDA recommends specific non-clinical safety studies to support the declaration.


    The guidelines recommend a three-month toxicity study to evaluate the safety of initiating human administration, dose escalation, and chronic treatment.


    In addition, the draft guidelines also give considerations for the first human dose and dose escalation.


    Author: Zhilin-Clover

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.